Literature DB >> 9857238

Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine.

S Sumi1, K Kidouchi, M Kondou, K Hayashi, K Dobashi, M Kouwaki, H Togari, Y Wada.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) deficiency with a defect of the pyrimidine catabolic pathway has recently become the focus of considerable attention, due to the severe 5-fluorouracil (5-FU) toxicities occurring in DPD deficiency patients. Studies also suggest that 5-FU toxicities could occur in another pyrimidine metabolic disorder, dihydropyrimidinuria (DHPuria). This study shows that urinary dihydrothymine (DHT) and thymine (THY) are useful indexes for detection of DPD deficiency and DHPuria. We measured urinary DHT and THY in 276 Japanese adults to establish reference ranges. When males and females were compared, both DHT and THY levels were found to be significantly higher in females. The reference ranges (mean +/- SD with logarithmic values) for males were found to be 1.56-5.70 micromol/g of creatinine for DHT and 0.40-1.47 micromol/g of creatinine for THY. The reference ranges for females were found to be 1.89-8.33 micromol/g of creatinine for DHT and 0.58-2.30 micromol/g of creatinine for THY. In addition to this study we analyzed a DPD deficiency case and a DHPuria case. In the DPD deficiency case, the THY concentrations of all urine samples were out of the reference range. However, uracil levels in most of the samples were within the normal range. The DHPuria case excreted large amounts of DHT and dihydrouracil, both out of the normal range.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857238     DOI: 10.3892/ijmm.2.4.477

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  2 in total

1.  Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

Authors:  Suminobu Ito; Takeshi Kawamura; Makoto Inada; Yoshiharu Inoue; Yukihiro Hirao; Toshihisa Koga; Jun-ichi Kunizaki; Takefumi Shimizu; Hitoshi Sato
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 2.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.